Literature DB >> 6252837

In vitro susceptibility of gram-negative bacilli from pediatric patients to moxalactam, cefotaxime, Ro 13-9904, and other cephalosporins.

S Shelton, J D Nelson, G H McCracken.   

Abstract

Moxalactam, Ro 13-9904, cefotaxime, cefoperazone, older cephalosporins, and four aminoglycosides were tested in vitro against 432 strains of gram-negative bacteria isolated from pediatric patients. The new drugs were uniformly active against coliform bacilli obtained from patients with meningitis and against aminoglycoside-resistant coliform bacilli.

Entities:  

Mesh：

Substances：

Year:  1980        PMID： 6252837      PMCID： PMC284026          DOI： 10.1128/AAC.18.3.476

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  2 in total

1.  A controlled study of intrathecal antibiotic therapy in gram-negative enteric meningitis of infancy. Report of the neonatal meningitis cooperative study group.

Authors:  G H McCracken; S G Mize
Journal:  J Pediatr       Date:  1976-07       Impact factor: 4.406

2.  Intravenous cefotaxime in children with bacterial meningitis.

Authors:  B H Belohradsky; K Bruch; D Geiss; D Kafetzis; W Marget; G Peters
Journal:  Lancet       Date:  1980-01-12       Impact factor: 79.321
  2 in total
  22 in total

1.  Comparative in vitro activity of ceftriaxone against anaerobic bacteria.

Authors:  R D Rolfe; S M Finegold
Journal:  Antimicrob Agents Chemother       Date:  1982-08       Impact factor: 5.191

2.  In vitro susceptibility of Haemophilus influenzae and neisseria gonorrhoeae to Ro 13-9904 in comparison with other beta-lactam antibiotics.

Authors:  W S Ng; P Y Chau; K Arnold
Journal:  Antimicrob Agents Chemother       Date:  1981-05       Impact factor: 5.191

3.  In vitro activity of second and third generation cephalosporins against ampicillin susceptible and resistant haemophilus influenzae.

Authors:  J L Burns; K Wong; A L Smith
Journal:  Infection       Date:  1988 Sep-Oct       Impact factor: 3.553

Review 4.  Ceftriaxone. A review of its antibacterial activity, pharmacological properties and therapeutic use.

Authors:  D M Richards; R C Heel; R N Brogden; T M Speight; G S Avery
Journal:  Drugs       Date:  1984-06       Impact factor: 9.546

Review 5.  The cephalosporin compounds in severe neonatal infection.

Authors:  U B Schaad
Journal:  Eur J Pediatr       Date:  1984-01       Impact factor: 3.183

6.  High performance liquid chromatographic determination of moxalactam in human plasma and cerebrospinal fluid.

Authors:  J Nielsen; G Karlaganis; H M von Hattingberg; U B Schaad
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

7.  Biliary excretion of amoxycillin and ceftriaxone after intravenous administration in man.

Authors:  D P Maudgal; J D Maxwell; L J Lees; R N Wild
Journal:  Br J Clin Pharmacol       Date:  1982-08       Impact factor: 4.335

8.  Pharmacokinetics and bacteriological efficacy of cefoperazone, ceftriaxone, and moxalactam in experimental Streptococcus pneumoniae and Haemophilus influenzae meningitis.

Authors:  G H McCracken; J D Nelson; L Grimm
Journal:  Antimicrob Agents Chemother       Date:  1982-02       Impact factor: 5.191

9.  Ceftriaxone: in vitro studies and clinical evaluation.

Authors:  J W Gnann; W E Goetter; A M Elliott; C G Cobbs
Journal:  Antimicrob Agents Chemother       Date:  1982-07       Impact factor: 5.191

10.  Single-dose pharmacokinetics of ceftriaxone in infants and young children.

Authors:  U B Schaad; K Stoeckel
Journal:  Antimicrob Agents Chemother       Date:  1982-02       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.